Cybin Inc. (CYBN.NE)
| Previous Close | 1.0100 |
| Open | 1.0400 |
| Bid | 1.1400 x 0 |
| Ask | 1.1600 x 0 |
| Day's Range | 1.0400 - 1.2100 |
| 52 Week Range | 0.5000 - 3.5800 |
| Volume | |
| Avg. Volume | 116,937 |
| Market Cap | 184.414M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3930 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
TORONTO, August 17, 2022--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™", and its partner Clinilabs Drug Development Corporation ("Clinilabs"), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency ("DEA") has granted a Schedule I license to support the first-in-human Phase
- Business Wire
Cybin Announces Results of Shareholders’ Meeting
TORONTO, August 15, 2022--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", is pleased to announce the voting results for each of the matters presented at the Company’s annual meeting of shareholders held on August 15, 2022 (the "Meeting"). There were 71 shareholders represented in person or by proxy at the Meeting holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued
- Business Wire
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
TORONTO, August 09, 2022--First paragraph, first sentence of release should read: Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a biopharmaceutical company focused on progressing "Psychedelics to TherapeuticsTM", announced today that it has established an at-the-market equity program (the "ATM Program") that allows Cybin to issue and sell up to USD$35,000,000 of common shares (Instead of Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a biophar
